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Background: Most DNA-damaging chemotherapeutic agents activate the transcription factor nuclear factor κB
(NF-κB). However, NF-κB activation can either protect from or contribute to the growth suppressive effects of the
agent. We previously showed that the DNA-methylating drug temozolomide (TMZ) activates AKT, a positive
modulator of NF-κB, in a mismatch repair (MMR) system-dependent manner. Here we investigated whether NF-κB is
activated by TMZ and whether AKT is involved in this molecular event. We also evaluated the functional
consequence of inhibiting NF-κB on tumor cell response to TMZ.
Methods: AKT phosphorylation, NF-κB transcriptional activity, IκB-α degradation, NF-κB2/p52 generation, and RelA
and NF-κB2/p52 nuclear translocation were investigated in TMZ-treated MMR-deficient (HCT116, 293TLα-) and/or
MMR-proficient (HCT116/3-6, 293TLα+, M10) cells. AKT involvement in TMZ-induced activation of NF-κB was
addressed in HCT116/3-6 and M10 cells transiently transfected with AKT1-targeting siRNA or using the isogenic
MMR-proficient cell lines pUSE2 and KD12, expressing wild type or kinase-dead mutant AKT1. The effects of
inhibiting NF-κB on sensitivity to TMZ were investigated in HCT116/3-6 and M10 cells using the NF-κB inhibitor
NEMO-binding domain (NBD) peptide or an anti-RelA siRNA.
Results: TMZ enhanced NF-κB transcriptional activity, activated AKT, induced IκB-α degradation and RelA nuclear
translocation in HCT116/3-6 and M10 but not in HCT116 cells. In M10 cells, TMZ promoted NF-κB2/p52 generation
and nuclear translocation and enhanced the secretion of IL-8 and MCP-1. TMZ induced RelA nuclear translocation
also in 293TLα+ but not in 293TLα- cells. AKT1 silencing inhibited TMZ-induced IκB-α degradation and NF-κB2/p52
generation. Up-regulation of NF-κB transcriptional activity and nuclear translocation of RelA and NF-κB2/p52 in
response to TMZ were impaired in KD12 cells. RelA silencing in HCT116/3-6 and M10 cells increased TMZ-induced
growth suppression. In M10 cells NBD peptide reduced basal NF-κB activity, abrogated TMZ-induced up-regulation
of NF-κB activity and increased sensitivity to TMZ. In HCT116/3-6 cells, the combined treatment with NBD peptide
and TMZ produced additive growth inhibitory effects.
Conclusion: NF-κB is activated in response to TMZ in a MMR- and AKT-dependent manner and confers protection
against drug-induced cell growth inhibition. Our findings suggest that a clinical benefit could be obtained by
combining TMZ with NF-κB inhibitors.
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The nuclear factor κB (NF-κB) family of transcription
factors regulates the expression of multiple target genes
involved in a variety of physiological and pathological
processes, including inflammation, innate and adaptive
immune response, angiogenesis, tumorigenesis, and me-
tastasis [1-3].
In mammals, the NF-κB family is composed of RelA
(p65), c-Rel, RelB, NF-κB1 (p50) and NF-κB2 (p52), which
can form homo- and heterodimers. The latter two family
members are produced as precursor proteins, p105 and
p100, respectively, which are subjected to cotranslational
(p105) or stimulus-dependent (p100) processing to the
mature forms [1-3].
In resting cells, NF-κB homo- and heterodimers are
maintained latent in the cytoplasm through the association
with inhibitory proteins (inhibitors of κB, IκBs). In re-
sponse to a variety of signals which act through membrane
and/or cytoplasmic receptors (e.g. pro-inflammatory cyto-
kines, ligands for Toll-like receptors, engagement of B and
T cell receptors), IκBs are degraded rendering NF-κB free
to translocate into the nucleus and regulate gene transcrip-
tion [1-3]. In this regard, two main pathways of NF-κB ac-
tivation can be recognized, namely the “canonical” and the
“non-canonical” pathway, both converging on the activa-
tion of the IκB kinase (IKK) complex. The IKK complex, in
turn, phosphorylates IκBs marking them for ubiquitin-
dependent degradation [1,2,4]. NF-κB activation through
the canonical pathway involves the IKK complex compris-
ing the catalytic subunits IKK-α and IKK-β as well as the
regulatory subunit NF-κB essential modulator (NEMO/
IKKγ) and, in most cells, leads to IκB-α degradation and
nuclear translocation of p50/RelA dimers [1-3]. The non-
canonical pathway, predominantly active in B cells, is typic-
ally triggered by some members of the TNF cytokine family
and it has been suggested to be dependent on the activa-
tion of IKK-α homodimers [1,2,4]. In this pathway, which
does not require the function of NEMO, activation of IKK
leads to phosphorylation and proteolytic cleavage of p100
to produce the mature NF-κB2/p52 subunit. Subsequently,
p52/RelB dimers translocate into the nucleus [1,2,4].
The canonical and non-canonical pathways of NF-κB
activation can also be engaged by a number of genotoxic
agents [5-8]. The signal transduction mechanisms link-
ing DNA damage in the nucleus with NF-κB activation
in the cytoplasm have not been fully elucidated yet, but
they appear to require the function of ATM (Ataxia-Tel-
angiectasia Mutated) and NEMO [5-8]. Notably, NF-κB
activation in response to DNA damage can result in ei-
ther protection from or sensitization to the genotoxic
agent, depending on the cell line and the nature and/or
amount of the agent [5-8].
Temozolomide (TMZ) is a methylating triazene com-
pound approved for the treatment of newly diagnosedglioblastoma and refractory anaplastic astrocytoma [9,10].
Although not approved for this indication, TMZ is fre-
quently used off-label for the treatment of metastatic
melanoma. Currently, a number of clinical trials are
evaluating TMZ in combination therapies for other solid
tumors, including colorectal cancer (http://www.clinical-
trials.gov).
The antitumor activity of TMZ is primarily due to the
methylation of the O6 position of guanine (O6-G) in
DNA. If not repaired, O6-methylguanine (O6-MeG) fre-
quently mispairs with thymine during DNA duplication.
O6-MeG:T mismatches then trigger the intervention of
the mismatch repair (MMR) system [11,12], which, how-
ever, fails to find a correct partner for O6-MeG. As a
consequence, futile cycles of repair generates nicks in
the DNA and activates a signaling cascade resulting in
cell cycle arrest at the G2 phase of the second cell doub-
ling event, which is followed by either apoptosis, mitotic
catastrophe, or a senescence-like state [12-19]. Methyl
adducts at O6-G are specifically removed by the DNA
repair protein O6-methylguanine-DNA methyltransfer-
ase (MGMT) [20,21]. Therefore, MMR-proficient cells
endowed with elevated MGMT activity are resistant to
TMZ, but they can be sensitized to the drug by MGMT
inhibitors [e.g. O6-benzylguanine (BG)] [20,21]. MMR-
deficient cells are, instead, highly resistant to TMZ
regardless of their MGMT activity (Additional file 1:
Figure S1).
The serine/threonine kinase AKT is a critical regulator
of major cellular processes, including gene expression,
glycogen metabolism, migration, proliferation, and sur-
vival [22]. Once activated, AKT controls cellular functions
through phosphorylation of a large variety of substrates,
including several molecules involved in the NF-κB signal-
ing pathways [1,3,23,24]. Recently, we have demonstrated
that in colon and breast cancer cells, treatment with TMZ
provokes AKT activation that counteracts the growth sup-
pressive effects of the drug [25]. Therefore, in the present
study we investigated whether TMZ-induced activation of
AKT results in the triggering of the NF-κB signalling path-
way. Moreover, we evaluated whether NF-κB inhibition,
achieved through either RNA interference technology or
the use of a selective NF-κB inhibitor, is able to increase
tumor cell sensitivity to TMZ.
Methods
Cell lines
The MMR-proficient human metastatic melanoma cell
line M10 [26] was kindly provided by Dr. D. Del Bufalo
(Regina Elena Cancer Institute, Rome, Italy) and cul-
tured in GIBCO™ RPMI-1640 medium (Invitrogen Cor-
poration, Carlsbad, CA) supplemented with 10% fetal
calf serum (FCS) (GIBCOW), 2 mM GIBCO™ L-Glutam-
ine, and 50 μg/ml GIBCO™ Gentamicin.
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HCT116 and its MMR-proficient subline HCT116/3-6
were kindly provided by Dr. G. Marra (Institute of Mo-
lecular Cancer Research, University of Zurich, Zurich,
Switzerland). HCT116 cells have a hemizygous non-
sense mutation in the hMLH1 gene located on chromo-
some 3 [27]. The HCT116/3-6 subline was created by
microcell chromosome transfer of a single normal
human chromosome 3 into HCT116 cells [28]. The cell
lines were maintained in McCoy’s 5A medium (Sigma-
Aldrich, St. Louis, MO) supplemented with 10% FCS
(GIBCOW), 2 mM GIBCO™ L-Glutamine, 50 μg/ml
GIBCO™ Gentamicin and, in the case of HCT116/3-6
cells, 400 μg/ml G418 (Sigma-Aldrich).
The human embryonic kidney (HEK) 293T-MutLα-/Lα+
cell line (hereafter referred to as 293T±Lα) was a gift of
Prof. J. Jiricny (Institute of Molecular Cancer Research,
University of Zurich, Zurich, Switzerland). The cell line
was derived from the hMLH1-deficient cells HEK293T
[29] by stable transfection with a vector carrying the
hMLH1 cDNA under the control of the inducible Tet-Off
expression system [29]. In the absence of doxycycline the
cell line expresses the hMLH1 protein. Conversely, in the
presence of the drug the transcription of hMLH1 is turned
off [29]. The cell line was grown in DMEM with Eagle
salts (GIBCOW), supplemented with 10% Tet-System
approved FCS (BD Biosciences Pharmigen, San Diego,
CA), 2 mM GIBCO™ L-Glutamine, 50 μg/ml GIBCO™
Gentamicin, 100 μg/ml Zeocin (Invitrogen Corporation),
and 300 μg/ml Hygromycin B (Roche Applied Science,
Mannheim, Germany). To turn off hMLH1 expression the
cells were cultured for 7 days in the presence of 50 ng/ml
doxycycline (Sigma-Aldrich).
The MCF-7/KD12 cell line (hereafter referred to as
KD12) was generated by stable transfection of an expres-
sion vector encoding a dominant-negative kinase-dead
form of AKT1 (mutation K179M) into the MCF-7/B1
clone, derived from the MMR-proficient breast cancer
cell line MCF-7 [25]. The MCF-7/pUSE2 cell line (here-
after referred to as pUSE2) was obtained by transfection
of the empty vector into the same cell clone. Both cell
lines were maintained in the culture medium described
for M10 cells, supplemented with 400 μg/ml G418.
M10, HCT116, HCT116/3-6, and MCF-7 cell lines
were previously shown to be MGMT-proficient [30-32].
The 293T±Lα cell line does not express MGMT [29].
HCT116 and MCF-7 cells have been previously
screened for mutation in HRAS, NRAS, KRAS, BRAF and
PIK3CA [33]. HCT116 cells were found to harbor a het-
erozygous oncogenic mutation in KRAS (p.G13D) and
PIK3CA (p.H1047R), whereas MCF-7 cells were found to
be mutated in PIK3CA (p.E545K) [33]. To assess whether
constitutive activation of the mitogen-activated protein
kinase (MAPK) and/or PI3K/AKT signalling pathways wasalso present in M10 cells, we performed a mutational ana-
lysis of NRAS, BRAF and PIK3CA in these cells. Briefly,
the complete coding regions and intron-exon boundaries
of exons 2 and 3 in NRAS, exon 15 in BRAF, and exons 9
and 20 in PIK3CA were directly sequenced using an auto-
mated fluorescence-based cycle sequencer (ABI PRISMW
3100, Life Technologies, Carlsbad, CA) as previously
described [34]. The M10 cell line was found to be mutated
in BRAF (p.V600E) and wild-type in NRAS and PIK3CA.
Drugs and reagents
TMZ was kindly provided by Merck Sharp & Dohme-
Merck & Co., Inc. (Whitehouse Station, NJ) and was al-
ways prepared freshly in culture medium, because the
drug readily decomposes in aqueous solution. The NF-
κB-inhibitor NEMO-binding domain (NBD) peptide [35]
was purchased from Alexis Corporation (San Diego, CA)
as a solution of 10 mM in phosphate buffered saline
(PBS). The MGMT-inhibitor BG was purchased from
Sigma-Aldrich and dissolved in ethanol (2.4 mg/ml).
Both inhibitors were stored as stock solutions at −80°C,
and diluted in culture medium just before use. In all
assays, with the exception of those performed with 293T
±Lα cells, BG was used at the final concentration of 10
μM, added to the cells 2 h before TMZ and left into the
culture up to the end of TMZ treatment. At the concen-
tration used, BG did not affect cell proliferation (data
not shown). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide (MTT), and 4’-6-Diamidino-2-pheny-
lindole (DAPI) were purchased from Sigma-Aldrich. MTT
was prepared at a concentration of 5 mg/ml in PBS, and
stored at 4°C.
Reagents for SDS-polyacrylamide gel electrophoresis
were all purchased from Bio-Rad Laboratories (Hercules,
CA).
NF-κB luciferase reporter assay
HCT116/3-6, HCT116, M10, pUSE2 and KD12 cells were
seeded into 24-well plates (BD Falcon™, Becton, Dickin-
son and Company, Franklin Lakes, NJ) and allowed to
adhere at 37°C for 18 h. The cells were then transiently
co-transfected with 3 μg (M10) or 0.075 μg (HCT116/
3-6, HCT116) or 0.3 μg (pUSE2 and KD12) of the
NFκB-responsive firefly luciferase reporter pNF-κB-Luc
(Stratagene, La Jolla, CA) and 250 ng (M10) or 6.25 ng
(HCT116/3-6, HCT116) or 25 ng (pUSE2 and KD12) of
the Renilla luciferase expression vector pRL-null (Pro-
mega Corporation, Madison, WI) using Lipofectamine™
2000 Reagent (Invitrogen Corporation) according to the
manufacturer’s protocol. Twenty-four hours after trans-
fection, cells were exposed to 50 μM TMZ plus BG or
to BG alone as a control. After 48 and 72 h of culture,
the cells were lysed and luciferase assays were per-
formed using the Dual-LuciferaseW Reporter Assay
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For each sample, firefly luciferase activity was normal-
ized to Renilla luciferase activity and then to the total
protein amount used in the assay.
To evaluate the effect of NBD peptide on NF-κB activ-
ity, M10 cells were plated and co-transfected with the
pNF-kB-Luc and pRL-null vectors as described above.
Twenty-four hours after transfection, 50 μM NBD pep-
tide was added to the cultures. After additional 24 h of
incubation, untreated and NBD peptide-treated cells
were exposed to 50 μM TMZ plus BG or to BG alone.
Seventy-two hours after drug addition, the cells were
lysed and luciferase assays were performed as described
above.
Enzyme-Linked Immunosorbent Assay (ELISA)
M10 cells were seeded in 100-mm plates (BD Falcon™)
and allowed to adhere at 37°C for 18 h. The cells were
then exposed to 50 μM TMZ plus BG or BG alone for
48 or 72 h. The amounts of interleukin 8 (IL-8) and
monocyte chemoattractant protein-1 (MCP-1) released
into the culture medium were determined by ELISA
using the OptEIA Set for human IL-8 or MCP-1 (BD
Biosciences Pharmigen) according to the manufacturer's
instructions. Proteins were normalized to the number of
total cells counted in each culture at the time of super-
natant collection.
Western blot analysis
Rabbit polyclonal antibodies against AKT and phospho-
AKT (Ser473) were purchased from Cell Signaling Tech-
nology, Inc. (Beverly, MA). Rabbit polyclonal antibodies
against IκB-α (C-21), NF-κB2/p52 (K27) and RelA (C20),
as well as mouse monoclonal antibody (mAb) against
lamin A/C (346) were purchased from Santa Cruz Bio-
technology, Inc., (Santa Cruz, CA). mAb against actin
(Clone AC-40) was obtained from Sigma-Aldrich.
Whole cell extracts and nuclear extracts were prepared
as described previously [18,36]. Twenty-five μg (whole
cell extracts) or 10 μg (nuclear extracts) of proteins per
sample were run on a 10% SDS-polyacrilamide gels,
transferred to nitrocellulose membranes (Amersham
Biosciences, Buckinghamshire, UK) and blocked with 5%
non-fat milk in Tris-buffered saline supplemented with
0.1% Tween 20 for 1 h at room temperature. The mem-
branes were then incubated in the same solution over-
night at 4°C with primary antibodies at the following
dilutions: anti-AKT 1:1000; anti-phospho-AKT 1:500;
anti-IκB-α 1:200; anti-NF-κB2/p52 1:200; anti-RelA 1:500;
anti-lamin A/C 1:500, anti-actin 1:1000. The latter two
antibodies were used as internal standards for loading.
Immunodetection was carried out using appropriate
horseradish peroxidase-linked secondary antibodies and
enhanced chemiluminescence (ECL) detection reagents(Amersham Biosciences). Where indicated, films were
scanned on a GS-710 Calibrated Imaging Densitometer
and analyzed by means of Quantity One Software Version
4.1.1 (Bio-Rad Laboratories).Transient transfection with small interfering RNA (siRNA)
targeting RelA
Oligonucleotide siRNA targeting RelA (AGCACAGAUAC
CACCAAGA) (siNFp65) and the corresponding scramble
oligonucleotide (GAUCGCGAGCCAAACUAUA) (scrNFp65)
to be used as a control were purchased from Sigma-
Proligo (The Woodlands, TX).
For Western blot analysis, HCT116/3-6 and M10 cells
were suspended in culture medium without antibiotics,
seeded into 60-mm dishes (BD Falcon™) and allowed to
adhere at 37°C for 18 h. The cells were then transfected
with 100 nM siNFp65 or scrNFp65 using Oligofecta-
mine™ Reagent (Invitrogen Corporation) according to
the manufacturer’s protocol. As an additional control
group, the cells were treated with the transfection re-
agent alone (mock-transfected cells). After 72 h of cul-
ture at 37°C, the cells were recovered, plated and
subjected to a second transfection as described above.
Total cell extracts were prepared 7 days after the second
transfection.
For chemosensitivity assays, HCT116/3-6 and M10
cells recovered after the first transfection were seeded
into 96-well plates (BD Falcon™), allowed to adhere at
37°C for 18 h, and then subjected to the second transfec-
tion. After 24 h of incubation, the cells were exposed to
graded concentrations of TMZ plus BG or to BG alone.
The plates were incubated at 37°C for 6 days and cell
proliferation was then evaluated by the MTT assay, as
previously described [31]. Four replica wells were used for
each group. TMZ concentration producing 50% inhibition
of cell growth (i.e. IC50), was calculated on the regression
line in which absorbance values at 595 nm were plotted
against the logarithm of drug concentration.Transient transfection with siRNA targeting AKT1
Oligonucleotide siRNA targeting AKT1 (CUCACAGCC
CUGAAGUACU) (siAKT1) and the corresponding scramble
oligonucleotide (GAUCCUAUAUUCGGUUAGU) (scrAKT1)
to be used as a control were purchased from Sigma-Proligo.
For Western blot analysis, M10 and HCT116/3-6 cells
were suspended in culture medium without antibiotics,
seeded into 6-well plates (BD Falcon™), allowed to ad-
here at 37°C for 18 h, and then transfected with 50 nM
siAKT1 or scrAKT1 using Lipofectamine™ RNAiMAX
Reagent. (Invitrogen Corporation). Twenty-four hours
after transfection, the cells were incubated with 50 μM
TMZ plus BG or with BG alone. Whole cell extracts
were prepared after 72 h of TMZ exposure.
Caporali et al. Journal of Translational Medicine 2012, 10:252 Page 5 of 14
http://www.translational-medicine.com/content/10/1/252Treatment with NBD peptide for proliferation assays
To evaluate the effect of NBD peptide on cell prolifera-
tion, M10 and HCT116/3-6 cells were seeded into 96-well
plates (BD Falcon™), allowed to adhere at 37°C for 18 h,
and then incubated with concentrations of NBD peptide
ranging between 12.5 and 100 μM. After 6 days of culture,
cell proliferation was evaluated by the MTT assay, and the
IC50 values of NBD peptide were determined. The mean
IC50 value of NBD peptide was 63.93 μM (four independ-
ent experiments, standard error of the mean: 3.16 μM)
and 72.97 μM (three independent experiments, standard
error of the mean: 4.03 μM) for M10 and HCT116/3-6
cells, respectively. On this basis, the NBD concentration
of 50 μM, producing about 30-35% of growth inhibition in
both cell lines, was selected for the subsequent studies.
To investigate the effects of NBD peptide on cell sensi-
tivity to TMZ, M10 and HCT116/3-6 cells were plated
and allowed to adhere as described above, and then left
untreated or exposed to 50 μM NBD peptide for 24 h.
Thereafter, the cells were incubated with graded concen-
trations of TMZ plus BG or with BG alone. Cell prolif-
eration was evaluated by the MTT assay after 5 days of
TMZ exposure.
Senescence-associated β-galactosidase (SA-β-Gal) staining
M10 and HCT116/3-6 cells were plated into 24-well
plates (BD Falcon™), allowed to adhere at 37°C for 18 h
and then left untreated or exposed to 50 μM NBD pep-
tide for 24 h. The cells were then incubated with 50 μM
TMZ plus BG or with BG alone for 4 days. At the end
of the incubation period, the cells were fixed and stained
using the Senescence β-Galactosidase Staining Kit from
Cell Signaling Technology Inc., according to the manu-
facturer’s protocol. The percentage of SA-β-Gal positive
cells was determined by counting five different randomly
selected fields (each comprising 50–150 cells) per sam-
ples under a bright-field microscope (10x magnification).
Analysis of senescence-associated heterochromatin foci
(SAHF)
M10 and HCT116/3-6 cells were grown on 8-well
Lab-TekW II chamber slides (ThermoFisher Scientific,
Rochester, NY) for 18 h and then left untreated or
exposed to 50 μM NBD peptide for 24 h. Afterward, the
cells were incubated with 50 μM TMZ plus BG or with
BG alone for 7 days, and then fixed with 4% paraformal-
dehyde. After washing with PBS, the cells were permea-
bilized with 0.2% Triton-X-100/PBS at room temperature
for 10 min. The cells were then washed twice with PBS,
incubated with 1 μg/ml DAPI at room temperature for 1
min, and washed again in PBS. Slides were mounted in a
90% glycerol/PBS solution and examined using a fluores-
cence microscope (Axioskop 2 microscope and AxioCam
camera, Zeiss, Thornwood, NY).Statistical analysis
Statistical significance among different TMZ IC50 values,
different levels of IL-8 and MCP-1 secretion, and differ-
ent percentage of senescent cells was assessed using
Student’s t test analysis. Statistical significance among
different values of firefly luciferase activity/μg protein
was assessed using paired Student’s t test analysis.
Results
TMZ treatment increases NF-κB transcriptional activity in
an MMR-dependent manner
To investigate whether NF-κB transcriptional activity
increases in response to TMZ and whether a functional
MMR is required for this molecular event, M10,
HCT116/3-6 and HCT116 cells were transfected with an
NFκB-responsive luciferase reporter (pNF-κB-Luc) and
then cultured in the presence of the drug. Luciferase
assays performed after 48 and 72 h of exposure to TMZ
evidenced a significant increase of pNF-κB-Luc reporter
activity in the MMR-proficient cell lines M10 and
HCT116/3-6 (Figure 1A). In contrast, no TMZ-induced
change in pNF-κB-Luc reporter activity was detected in
MMR-deficient HCT116 cells (Figure 1A).
IL8 and CCL2 genes, encoding IL-8 and MCP-1, re-
spectively, are transcriptional targets of NF-κB [37,38].
Therefore, to further confirm the increase of NF-κB
transcriptional activity in cells exposed to TMZ, we eval-
uated the effect of the drug on the secretion of these
cytokines by M10 cells. With respect to the supernatants
derived from control cultures, an increase of about 3-
fold of both IL-8 and MCP-1 levels was detected in the
supernatants obtained from the cultures exposed to
TMZ for 72 h (Figure 1B).
TMZ treatment induces AKT phosphorylation, IκB-α
degradation and nuclear translocation of RelA in an
MMR-dependent manner
We have previously demonstrated that in response to
TMZ, AKT is phosphorylated on Ser473 and function-
ally activated in the MMR-proficient cell line HCT116/
3-6, but not in its MMR-deficient counterpart HCT116
[25]. On the other hand, it has been shown that activa-
tion of AKT in response to several stimuli indirectly pro-
motes IκB-α degradation and nuclear translocation of
p50/RelA dimers [39-44]. On these bases, M10, HCT116/
3-6 and HCT116 cells were treated with TMZ and the
levels of AKT, phospho-AKT (Ser473) and IκB-α were
determined after 48 and 72 h of drug exposure. In agree-
ment with our previous data [25], TMZ-induced phos-
phorylation of AKT was observed in HCT116/3-6 but not
in the MMR-deficient HCT116 cells (Figure 2A). An in-
crease of phosphorylated AKT was also detected in TMZ-
treated M10 cells (Figure 2B). In both HCT116/3-6
(Figure 2A) and M10 (Figure 2B) cells, but not in
Figure 1 TMZ increases NF-κB transcriptional activity in MMR-
proficient but not in MMR-deficient cells. (A) The cells were
transiently co-transfected with the pNF-κB-Luc and pRL-null vectors,
and 24 h later exposed to 50 μM TMZ+10 μM BG or to BG alone.
Firefly luciferase activity was determined 48 and 72 h after drug
treatment and normalized to that of Renilla luciferase and then to
the total amount of protein used in the assays. Data are expressed
in terms of fold change (i.e. the ratio between firefly luciferase
activity/μg protein detected in TMZ-treated cells and that detected
in the corresponding control cells). Values represent the mean of at
least four independent experiments performed with duplicate
samples. Bars, standard error of the mean (SEM). *p<0.05, according
to paired Student’s t test analysis performed comparing firefly
luciferase activity/μg protein of TMZ-treated samples with that of
the corresponding controls. (B) M10 cells were cultured in the
presence of 50 μM TMZ+10 μM BG or BG alone and culture
supernatants were collected after 48 and 72 h of incubation. IL-8
and MCP-1 amount in the culture supernatants was then
determined by ELISA and expressed in terms of pg protein/106 cells.
Values represent the mean of three independent experiments
performed with duplicate samples. Bars, SEM. ** p<0.01 and *p<0.05,
according to Student’s t test analysis performed comparing the
chemokine amount detected in the culture supernatants of TMZ-
treated cells with that detected in the culture supernatants of the
corresponding controls.
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duction in the levels of IκB-α at the time points analyzed.
To examine whether nuclear translocation of NF-κB
occurred in response to TMZ, RelA levels were evalu-
ated in nuclear extracts of M10, HCT116/3-6 and
HCT116 cells exposed to the drug for 72 h. In both the
MMR-proficient cell lines, but not in HCT116 cells,
TMZ treatment induced an increase of about two-fold
of RelA nuclear content (Figure 2C).
To further confirm that TMZ-induced NF-κB activa-
tion requires a functional MMR system, nuclear trans-
location of RelA upon drug treatment was evaluated in
an additional pair of isogenic MMR-proficient and
MMR-deficient cell lines. As illustrated in Additional file
2: Figure S2, TMZ treatment increased the levels of nu-
clear RelA in the 293T±Lα cells cultured in the absence
of doxycycline (i.e. 293TLα+ cells), but not in the same
cells cultured in the presence of doxycycline able to turn
off the expression of hMLH1 (i.e. 293TLα- cells).
TMZ treatment promotes NF-κB2/p52 generation and
nuclear translocation in M10 but not in HCT116/3-6 cells
Previous studies have demonstrated that AKT can bind
and activate IKK-α leading to the processing of NF-κB2/
p100 and generation of the mature NF-κB/p52 subunit
[24]. We therefore investigated whether TMZ treatment
was also able to stimulate NF-κB2/p52 generation and
nuclear translocation in HCT116/3-6 and M10 cells. As
expected, NF-κB2/p52 expression was barely detectable
in total (Figure 3A) and nuclear (Figure 3B) extracts of
untreated M10 and HCT116/3-6 cells. Exposure to
TMZ caused an increase of total and nuclear content of
NF-κB2/p52 in M10 cells, whereas it did not affect the
expression or localization of the protein in HCT116/3-6
cells (Figure 3A and B).
AKT is necessary for NF-κB activation in response to TMZ
The analysis of AKT and NF-κB activation in MMR-
proficient and MMR-deficient cell lines exposed to TMZ
strongly indicated that AKT could be involved in drug-
induced activation of NF-κB. Additional experiments
were, therefore, performed to investigate whether inhib-
ition of AKT expression by RNA interference technology
was associated with an impairment of TMZ-induced
degradation of IκB-α and/or drug-induced NF-κB2/p52
generation.
As illustrated in Figure 4A, the amount of AKT pro-
tein was markedly reduced in siAKT1-transfected M10
and HCT116/3-6 cells as compared with their corre-
sponding scrAKT1-transfected controls. In both M10
and HCT116/3-6 cells, AKT1 silencing suppressed IκB-
α degradation in response to TMZ. Moreover, in M10
cells it also impaired drug-induced generation of NF-
κB2/p52. Notably, the basal levels of IκB-α appeared
Figure 2 TMZ induces AKT phosphorylation, IκB-α degradation, and RelA nuclear translocation in MMR-proficient but not in MMR-
deficient cells. HCT116/3-6, HCT116 and M10 cells were cultured in the presence of 50 μM TMZ+10 μM BG, or BG alone as a control, for 48 and
72 h (A, B) or 72 h (C). Total cell extracts (A, B) or nuclear extracts (C) were resolved on 10% SDS polyacrylamide gels, transferred to nitrocellulose
membranes and probed with antibodies against the indicated proteins. Anti-actin mAb or anti-lamin A/C mAb were used for equal loading
control. The immune complexes were visualized using ECL. For the indicated samples, the densitometric levels of phospho-AKT, IκB-α and RelA
were normalized to the respective levels of actin or lamin. Fold changes of protein expression in TMZ-treated samples were then calculated with
respect to the protein levels in the corresponding controls, to which the arbitrary value of 1.0 was assigned. The results are representative of
three (A, B) or two (C) independent experiments.
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scription of the NFKBIA gene, encoding IκB-α, is regu-
lated by NF-κB [45], it is possible to hypothesize that
AKT1 silencing results in a decrease of basal NF-κB
activity leading to reduced transcription of the NFKBIA
gene.
To confirm the involvement of AKT in NF-κB activa-
tion promoted by TMZ, drug-induced changes in pNF-
κB-Luc reporter activity and nuclear levels of RelA and
NF-kB2/p52 were evaluated in pUSE2 and KD12 cells.
The former cell line expresses wild type AKT and the
latter expresses a dominant-negative kinase-dead form
of AKT1. Luciferase assays performed after 72 h of ex-
posure to TMZ showed a significant increase of pNF-
κB-Luc reporter activity only in pUSE2 cells (Figure 4B).
Moreover, upon TMZ treatment, RelA and NF-κB2/p52
nuclear translocation was observed in pUSE2 but not in
KD12 cells (Figure 4C).
Inhibition of NF-κB increases tumor cell sensitivity to TMZ
Having demonstrated that NF-κB is activated in an
AKT-dependent manner in response to TMZ, experi-
ments were conducted to explore whether inhibition of
NF-κB activity could increase TMZ sensitivity of M10
and HCT116/3-6 cells. Indeed, we have previously
shown that KD12 cells, which do not activate NF-kB inresponse to TMZ, are approximately six-fold more sen-
sitive to the drug than pUSE2 cells [25]. M10 and
HCT116/3-6 cells were mock-transfected or transfected
with a siRNA targeting RelA (siNFp65) or a scrambled
siRNA (scrNFp65) and their sensitivity to TMZ was
evaluated by the MTT assay.
With respect to mock-transfected cells, a clear reduc-
tion of RelA levels was observed in siNFp65-transfected
cells, whereas the protein amount was unchanged in
scrNFp65-transfected cells (Figure 5A). Moreover, in-
hibition of RelA expression was accompanied by a sig-
nificant enhancement of HCT116/3-6 and M10 cell
sensitivity to TMZ (Figures 5B and C).
The NBD peptide is a cell permeable peptide spanning
the NBD of IKK-β and able to disrupt the NEMO-IKK
complex interaction [35]. In a first set of experiments,
we therefore investigated whether the NBD peptide was
able to impair TMZ-induced activation of NF-κB in
M10 cells and to increase their sensitivity to the drug.
Luciferase assays showed that the pNF-kB-Luc re-
porter activity detected in M10 cells exposed to NBD
peptide for 96 h was significantly lower than that
observed in control cells (Figure 6A). Moreover, NBD
peptide was able to suppress TMZ-induced activation of
NF-κB (Figure 6A). As illustrated in Figure 6B, a signifi-
cant increase in the growth suppressive effects of TMZ
Figure 3 TMZ promotes NF-κB2/p52 generation and nuclear
translocation in M10 cells. (A) The cells were cultured in the
presence of 50 μM TMZ+10 μM BG, or BG alone for the indicated
time. Total cell extracts were then prepared and analyzed for
NF-κB2/p52 expression by immunoblotting (see legend of Figure 2). The
results are representative of two independent experiments. (B) The cells
were cultured as described in (A) for 72 h. Nuclear extracts were
then prepared and analyzed for NF-κB2/p52 content as described in
(A) using anti-lamin A/C mAb for equal loading control. The results
are representative of two independent experiments.
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with the NBD peptide. Indeed, the IC50 values of TMZ
displayed by the cells exposed to NBD peptide were sig-
nificantly lower than those displayed by the cells not
treated with the peptide. This was true not only when
the IC50 values were determined with respect to control
cells treated with BG alone (CTRL-1), but also when
they were evaluated with respect to control cells exposed
to NBD peptide+BG (CTRL-2).
Previous studies have demonstrated that TMZ induces
senescence but not apoptosis in human melanoma cells
[46]. We therefore investigated whether the combined
treatment with NBD peptide and TMZ was more effective
than TMZ alone in inducing senescence in M10 cells.
The results illustrated in Figure 7A show that treat-
ment with NBD peptide caused a moderate, although
significant, increase in the percentage of SA-β-Gal posi-
tive cells whereas about 60% of the cells appeared
senescent in TMZ-treated cultures. Consistent with the
results of proliferation assays, the proportion of SA-β-
Gal positive cells detected in the cultures subjected to
the combined treatment with NBD peptide and TMZ
was significantly higher than that displayed by the cul-
tures exposed to each drug separately. Induction of sen-
escence in M10 cells treated with TMZ or NBD peptide
or the combination of both agents, was also confirmedby the appearance of SAHF in these cells. As shown in
Figure 7B, control cells displayed an uniform pattern of
DAPI staining, whereas drug-treated cells exhibited
punctuated DAPI foci, indicative of SAHF formation.
The growth suppressive effects of the association of
NBD peptide and TMZ were also evaluated in the
HCT116/3-6 cell line. Even in this case the association
of NBD peptide and TMZ was more effective than TMZ
alone in suppressing cell growth (Additional file 3:
Figure S3A) and inducing senescence (Additional file 3:
Figure S3B and S3C). However, in HCT116/3-6 cells,
the effects of the two drugs appear to be additive.
Discussion
Constitutive activation of NF-κB is frequently observed
in different types of cancer and has been correlated with
tumor development, progression and radio- and che-
moresistance. Actually, NF-κB regulates the expression
of a wide array of genes that actively participate in con-
trolling cell proliferation and survival, as well as angio-
genesis and metastasis [1-3]. Targeting either activation
or function of NF-κB is therefore considered a promis-
ing strategy to inhibit tumor growth and metastasis and
to increase the efficiency of therapy [1-3].
A growing body of experimental evidence indicates
that, in addition to the large number of signals that act
through membrane and/or cytoplasmic receptors, vari-
ous DNA-damaging chemotherapeutic agents can lead
to NF-κB activation through initiating signals generated
in the nucleus [5-7]. However, the final outcome of
drug-induced up-regulation of NF-κB pathway, i.e. cell
protection from or sensitization to the growth suppres-
sive and/or death promoting effects of the drug, appears
to be dependent on the cell type and/or the nature and
the amount of the agent [5-7,47-50]. The dual role of
NF-κB activation in the modulation of tumor cell re-
sponse to chemotherapeutic agents appears to result
from the ability of this transcription factor to either acti-
vate or repress transcription of genes involved in cell
proliferation and survival, depending on which specific
post-translational modifications and interaction with
transcription co-activator or repressors occur in the ma-
lignant cells [1,3,23,51]. Therefore, the final outcome of
strategies targeting NF-κB to increase cancer cell re-
sponse to chemotherapy should be careful validated for
each tumor type and anticancer agent.
In this study, we demonstrate that exposure of MMR-
proficient malignant cells to a clinical relevant concen-
tration of TMZ caused activation of the NF-κB signalling
pathway. Indeed, using a NF-κB-responsive luciferase re-
porter, a 2-3-fold increase of NF-κB transactivation func-
tion was detected in HCT116/3-6, pUSE2 and M10 cells
treated with the drug. Consistent with this finding, ex-
posure to TMZ was able to enhance the secretion of IL-
Figure 4 AKT is involved in TMZ-induced activation of NF-κB. (A) The cells were transiently transfected with 50 nM siAKT1 or scrAKT (Scr)
and 24 h later exposed to 50 μM TMZ+10 μM BG, or to BG alone. After 72 h of culture, total cell extracts were analyzed for AKT, IκB-α and NF-
κB2/p52 expression by immunoblotting (see legend of Figure 2). The results are representative of two independent experiments. (B) The cells
were transiently co-transfected with the pNF-κB-Luc and pRL-null vectors and 24 h later incubated with 50 μM TMZ+10 μM BG or with BG alone.
Luciferase assays were performed after 72 h of drug exposure. Data are expressed in terms of fold change (see legend of Figure 1). Values
represent the mean of four independent experiments performed with duplicate samples. Bars, SEM. *p<0.05 according to paired Student’s t test
analysis performed comparing firefly luciferase activity/μg protein detected in TMZ-treated pUSE2 cells with that detected in the corresponding
control cells. The difference between firefly luciferase activity/μg protein of TMZ-treated KD12 cells and that detected in the corresponding
control cells was not statistically significant. (C) The cells were treated with 50 μM TMZ+10 μM BG or with BG alone for 72 h. Nuclear extracts
were then examined for the expression of RelA and NF-κB2/p52 by immunoblotting (see legend of Figure 2). The results are representative of
two independent experiments.
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cells. Notably, the expression of both IL-8 and MCP-1
has been associated with melanoma progression by
affecting the growth of tumor cells, angiogenesis and
metastasis [52].
In both HCT116/3-6, and M10 cells, degradation of
IκB-α and nuclear translocation of RelA were detected
after exposure to TMZ. An increase in the nuclear content
of RelA was also observed in drug-treated 293TLα+ cells.
Moreover, drug treatment stimulated the generation and
nuclear accumulation of the NF-κB2/p52 subunit in M10
cells. These findings indicate that TMZ-induced activation
of NF-κB can occur via the non-canonical and/or the ca-
nonical pathway, depending on the cell line. At present,
the cellular characteristics that allow NF-κB activation via
the non-canonical pathway upon cell exposure to TMZremain to be established. Previous studies have shown that
the expression of IKK-α and IKK-β as well as the propor-
tion of their homo- and heterodimers vary among differ-
ent cell types [53]. It is possible to speculate that the
engagement of the non-canonical pathway of NF-κB acti-
vation by TMZ depends, at least in part, on the levels of
IKK-α homodimer present in the cells.
TMZ-induced activation of NF-κB appears to be
strictly dependent on a functional MMR system. More-
over, AKT activation downstream the MMR system
appears to be involved in TMZ-induced triggering of
both the canonical and non-canonical pathway of NF-κB
activation. Indeed, the MMR-deficient cell line HCT116
failed to activate AKT and to degrade IκB-α in response
to the drug. Accordingly, HCT116 cells did not show
any increase of pNF-κB-Luc reporter activity and RelA
Figure 5 Inhibition of NF-κB expression by RNA interference
increases HCT116/3-6 and M10 cell sensitivity to TMZ. (A) The cells
were mock transfected (M) or subjected to two sequential
transfections with 100 nM scrNFp65 (Scr) or siNFp65 (siNF). Seven
days after the second transfection, whole cell extracts were prepared
and analyzed for RelA content by immunoblotting (see legend of
Figure 2). The results are representative of two independent
experiments. (B), (C) The cells were mock transfected or subjected to
two sequential transfections with 100 nM scrNFp65 or siNFp65.
Twenty-four hours after the second transfection, the cells were
incubated with the indicated concentrations of TMZ+10 μM BG or
with BG alone as a control. Proliferation was evaluated after 6 days
of drug exposure by the MTT assay. Data are expressed in terms of
percentage of growth of TMZ-treated cells with respect to control
cells. Each value represents the mean of four independent
experiments performed with quadruplicate samples. Bars, SEM.
**p<0.01, and *p<0.05, according to Student’s t test, comparing TMZ
IC50 values of siNFp65-transfected cells with those of mock-
transfected or scrNFp65-transfected cells. The difference between
TMZ IC50 values of scrNFp65 and those of mock-transfected cells
was not statistically significant.
Figure 6 NBD peptide inhibits NF-κB transcriptional activity
and increases the antiproliferative effect of TMZ in M10 cells.
(A) Melanoma cells were transiently co-transfected with the NF-κB-
Luc and pRL-null vectors and treated with NBD peptide, TMZ and
BG as described under “Methods”. Luciferase assays were performed
after 72 of drug exposure. Data are expressed in terms of fold
changes (i.e. the ratio between firefly luciferase activity/μg protein
detected in cells exposed to NBD+BG, or TMZ+BG or NBD+TMZ+BG
and that detected in cells treated with BG alone). Values represent
the mean of six independent experiments performed with duplicate
samples. Bars, SEM. Statistical analysis was performed on firefly
luciferase activity/μg protein values according to paired Student’s t
test. p values were as follows: **p<0.01, NBD+BG versus BG; #p<0.05,
TMZ+BG versus BG; §p<0.05 TMZ+BG versus NBD+TMZ+BG;
^^p<0.01, NBD+TMZ+BG versus NBD+BG. The differences between
firefly luciferase activity/μg protein of cells treated with NBD+TMZ
+BG and that of cells exposed to BG alone was not statistically
significant. (B) M10 cells were treated with NBD peptide, TMZ and
BG as described under “Methods” and assayed for proliferation by
the MTT assay. Percentage of growth of TMZ+BG-treated cells was
determined with respect to BG-treated cells (CTRL-1), and that of
NBD+TMZ+BG-treated cells with respect to either BG-treated cells
(CTRL-1) or NBD+BG-treated cells (CTRL-2). Values represent the
mean of four independent experiments. Bars, SEM. **p<0.01, and
*p<0.05, according to Student’s t test analysis, comparing TMZ IC50
values of NBD+TMZ+BG-treated cells with those of TMZ+BG-treated
cells.
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Figure 7 Combined treatment with NBD peptide and TMZ is
more effective than TMZ alone in inducing senescence in M10
cells. (A) M10 cells were left untreated or exposed to 50 μM NBD
peptide. After 24 h of culture, the cells were incubated with 50 μM
TMZ+10 μM BG or with BG alone, and monitored 96 h later for the
percentage of SA-β-Gal positive cells. Each value represents the
arithmetic mean of three independent experiments. Bar, SEM. p
values were calculated according to Student’s t test analysis.
**p<0.01, TMZ+BG-treated cells versus BG-treated cells; *p<0.05, NBD
peptide+BG-treated cells versus BG-treated cells; ††p<0.01, NBD
peptide+TMZ+BG-treated cells versus BG-treated cells; §§p<0.01 NBD
peptide+TMZ+BG-treated cells versus TMZ+BG-treated cells and
versus NBD+BG-treated cells; ^^p<0.01, TMZ+BG-treated cells versus
NBD peptide+BG cells. (B) M10 cells were treated with NBD peptide
and TMZ+BG as described in (A). After 7 days of culture, the cells
were stained with DAPI to visualize SAHF formation.
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MMR-proficient cell lines HCT116/3-6 and M10, which
activate AKT in response to TMZ, impairment of AKT1
expression by RNA interference markedly inhibited
drug-induced degradation of IκB-α and, in the case of
M10 cells, also drug-induced enhancement of NF-κB2/
p52 levels. Finally, TMZ was able to increase NF-κB-
dependent luciferase activity and to induce nuclear
translocation of RelA and NF-κB2/p52 in the MMR-proficient cell line pUSE2 but not in the isogenic KD12
cells, which express a dominant-negative kinase-dead
form of AKT1.
Previous investigations have demonstrated that AKT, via
different down-stream effector molecules, can promote
IκB-α degradation and p50/RelA or p50/RelB nuclear
translocation and can enhance the transactivation poten-
tial of RelA [43,44,54,55]. Moreover, it has been shown
that AKT can directly phosphorylate IKK-α leading to the
processing of p100 and nuclear accumulation of p52/RelB
dimers [24]. Our data are consistent with these findings,
even though further studies are required to detail further
the molecular mechanisms underlying AKT-dependent
NF-κB activation in TMZ-treated cells.
Regardless of the mechanisms involved in AKT-
dependent activation of NF-κB in TMZ-treated cells,
our results show that this molecular event has a pro-
survival function in tumor cells presenting constitutive
activation of the MAPK and/or PI3K/AKT signaling
pathways. Indeed, KD12 cells, which do not activate
NF-κB in response to TMZ are significantly more sensi-
tive to the drug than pUSE2 cells [25]. Moreover,
impairment of RelA expression by RNA interference
enhanced HCT116/3-6 and M10 cell sensitivity to
TMZ. Similarly, an increase of TMZ growth suppressive
effect was observed in M10 cells when the drug was
associated with a concentration of NBD peptide able to
attenuate basal NF-κB activity and to abrogate TMZ-
induced up-regulation of NF-κB activity. In these cells,
combined treatment with NBD peptide and TMZ induced
higher levels of senescence as compared with those caused
by each drug alone. Notably, in agreement with previous
studies [56] and with the role of NF-κB signaling pathway
in melanoma growth and survival [57,58], we found that
NBD peptide, as a single agent, was able to impair mel-
anoma cell proliferation in a concentration-dependent
manner. However, it must be pointed out that the NBD
peptide concentration exploited in combination with
TMZ only moderately affected M10 cell proliferation
when used alone. Moreover, TMZ IC50 values deter-
mined in presence of the NBD peptide were signifi-
cantly lower than those determined in the absence of
the NF-κB inhibitor, not only when they were evaluated
using BG-treated cells as control group, but also when
they were calculated using BG+NBD-treated cells as
control group. These findings show that TMZ is more
efficient in M10 cells when associated with the NF-κB
inhibitor. Notably, the same drug combination was also
found to be more active than TMZ alone in HCT116/
3-6 cells, although NBD peptide + TMZ showed only
additive effects on cell growth.
So far, a small number of studies have addressed the
effects of TMZ on NF-κB pathway with some discordant
results. Amiri et al. [59] demonstrated that exposure to
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cells and that bortezomib, an inhibitor of proteasome
able to impair NF-κB activation [60], potentiated TMZ-
induced suppression of melanoma cell growth both
in vitro and in a murine xenograft model. Using an NF-
κB-responsive luciferase reporter, Ohanna et al. [61] also
observed NF-κB activation in melanoma cells exposed to
TMZ. On the other hand, Yamini et al. [62] and Schmitt
et al. [63] demonstrated that TMZ treatment impaired
NF-κB transcriptional activity in glioblastoma cells. In
these cells, TMZ-induced activation of Chk1 led to pho-
phorylation of the NF-κB1/p50 subunit on Ser329, dis-
rupting the DNA binding ability of NF-κB dimers
containing this subunit [63].
The results of our study are consistent with the
findings of Amiri et al. [59] and Ohanna et al. [61].
However, we also show for the first time that, depend-
ing on the cell line, both the canonical and non-
canonical pathway of NF-κB activation can be elicited
by TMZ and that AKT plays a crucial role in the
drug-induced activation of both pathways. On the
other hand, the discrepancy between our results and
those of Yamini et al. [62] and Schmitt et al. [63]
might depend on the different cellular models utilized
to assess the effect of TMZ on NF-κB activity. Inter-
estingly, Hirose et al. [64] have shown that in glio-
blastoma cells TMZ treatment causes a decrease in
the endogenous levels of AKT phosphorylated on Ser473.
Previous investigations have also shown that activated
AKT is able to phosphorylate Chk1 on Ser280, leading to
inactivation and cytoplasmic localization of this check-
point kinase [65-67]. It is possible to speculate that TMZ
treatment could result in NF-κB activation or inhibition,
depending on whether in the cell line under investigation
the drug activates or not AKT in addition to Chk1. How-
ever, further studies are required to address this issue.
Conclusions
The present investigation demonstrates that in MMR-
proficient tumor cell lines of various histological deriv-
ation, NF-κB is activated in response to clinical rele-
vant concentrations of TMZ. Our study also provides,
for the first time, experimental evidence that AKT is
involved in TMZ-induced activation of NF-κB and that
this molecular event can occur through both the ca-
nonical and non-canonical pathway. Finally, our results
support a pro-survival role of TMZ-induced activation
of NF-κB. Several specific inhibitors of the NF-κB
pathway are currently being developed and will likely
enter clinical trials in the near future, either as single
agents or in combination with conventional chemo-
therapy [1-3,58]. Our findings strongly suggest that a
clinical benefit could be obtained by combining TMZ
with this type of biochemical modulators.Additional files
Additional file 1: Figure S1. Mechanisms of O6-MeG-dependent
growth suppression.
Additional file 2: Figure S2. TMZ induces nuclear translocation of RelA
in an MMR-dependent manner in 293T±Lα cells. 293T±Lα cells were
cultured in the absence (293TLα+ cells) or in the presence (293TLα- cells)
of 50 ng/ml doxycyclin for 7 days and then exposed to 2 μM TMZ for 72
h. The TMZ concentration used was selected on the basis of the high
susceptibility of these cells to TMZ (IC50: 1.27±0.14 μM, as obtained in
MTT assays). Nuclear extracts were prepared, resolved on 10% SDS
polyacrylamide gels, transferred to nitrocellulose membranes and probed
with antibodies against RelA. Anti-lamin A/C mAb was used for equal
loading control. The immune complexes were visualized using ECL. Fold
changes of RelA expression in TMZ-treated samples were calculated as
described in the legend of Figure 2. The results are representative of two
independent experiments.
Additional file 3: Figure S3. Effect of the NBD peptide on TMZ
sensitivity of HCT116/3-6 cells. (A) The cells were left untreated or
incubated with 50 μM NBD peptide for 24 h and then exposed to
increasing concentrations of TMZ plus 10 μM BG or to BG alone. After
additional 5 days of culture, cell proliferation was evaluated by the MTT
assay. Data are expressed in terms of percentage of growth, calculated
for TMZ+BG-treated cells with respect to BG-treated cells (CTRL-1), and
for NBD+TMZ+BG-treated cells with respect to either BG-treated cells
(CTRL-1) or NBD+BG-treated cells (CTRL-2). Each value represents the
mean of three independent experiments performed with quadruplicate
samples. Bars, SEM. **p<0.01, according to Student’s t test analysis,
comparing TMZ IC50 values of NBD+TMZ+BG-treated cells with those of
TMZ+BG-treated cells. (B) The cells were left untreated or exposed to 50
μM NBD peptide. After 24 h of culture, the cells were incubated with 50
μM TMZ+10 μM BG or with BG alone and monitored 96 h later for the
percentage of SA-β-Gal positive cells. Each value represents the
arithmetic mean of three independent experiments. Bar, SEM. p values
were calculated according to Student’s t test analysis. **p<0.01, TMZ+BG-
treated cells and NBD peptide+BG-treated cells versus BG-treated cells;
††p<0.01, NBD peptide+TMZ+BG-treated cells versus BG-treated cells;
§§p<0.01 NBD peptide+TMZ+BG-treated cells versus TMZ+BG-treated cells
and versus NBD+BG-treated cells; ^^p<0.01, TMZ+BG-treated cells versus
NBD peptide+BG cells. (C) HCT116/3-6 cells were treated with NBD
peptide and TMZ+BG as described in (B). After 7 days of culture, the cells
were stained with DAPI to visualize SAHF formation.
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